Compare BridgeBio Pharma Inc (BBIO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs GeneDx Holdings Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.44B). The key difference: BridgeBio Pharma Inc is far larger — about 6.7× GeneDx Holdings Corp's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| BBIO | WGS | |
|---|---|---|
Market Cap | $16.36B | $2.44B |
Sector | Health | Technology |
52-Week High | $90.17 | $167.51 |
52-Week Low | $47.29 | $34.51 |
Enterprise Value | $18.14B | $2.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
